Abstract |
Five TNO platinum compounds were evaluated for antitumor activities in two human ovarian carcinoma tumor lines grown in nude mice. The most active drug, TNO-38, was investigated in five additional lines with a known range of sensitivity to cisplatin. None of the new compounds showed superior activity to cisplatin. The slightly lower activity of TNO-38 as compared to the parent compound was reproducible in all tumor lines. Besides the similarity in the antitumor activity, a remarkable correspondence in platinum distribution and retention at 24 hr of TNO-38 and cisplatin could be observed. Chromatographic analysis of the compounds in their injection fluids showed single peaks for TNO-26 and TNO-38. The degradation products of the latter drugs may have affected their activity and toxicity. These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer.
|
Authors | E Boven, M M Nauta, H M Schluper, F Elferink, W J van der Vijgh, H M Pinedo |
Journal | European journal of cancer & clinical oncology
(Eur J Cancer Clin Oncol)
Vol. 21
Issue 10
Pg. 1253-60
(Oct 1985)
ISSN: 0277-5379 [Print] England |
PMID | 4076289
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- Platinum
- Cisplatin
|
Topics |
- Adenocarcinoma
(drug therapy)
- Animals
- Antineoplastic Agents
(therapeutic use)
- Brain
(metabolism)
- Cell Line
- Cisplatin
(metabolism, therapeutic use)
- Female
- Kidney
(metabolism)
- Liver
(metabolism)
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Organoplatinum Compounds
(metabolism, therapeutic use)
- Ovarian Neoplasms
(drug therapy, metabolism)
- Platinum
(metabolism, therapeutic use)
|